Tanaproget
Tanaproget is a nonsteroidal selective progesterone receptor modulator (SPRM) that was under development by Tanabe Seiyaku and later TAP Pharmaceutical Products for use in hormone replacement therapy (HRT) and as a contraceptive. However, development of the drug was discontinued and it was never marketed.
Pharmacology[edit | edit source]
Tanaproget has high affinity for the progesterone receptor (PR) and is a potent and selective agonist of the PR. It is nonsteroidal and, unlike progestogens, does not have off-target hormonal activity, such as androgen, glucocorticoid, or mineralocorticoid activity. This may result in fewer side effects and improved tolerability relative to progestogens.
Clinical development[edit | edit source]
Tanaproget was under development for use in HRT and as a contraceptive and reached phase II clinical trials for these indications. However, development was discontinued, reportedly due to poor bioavailability and the need for high doses.
See also[edit | edit source]
This pharmaceutical related article is a stub. You can help WikiMD by expanding it.
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD